Data are not publicly available and are housed at the Institute for Clinical Evaluative Sciences (ICES). Due to privacy laws in Ontario this data is not currently publicly shared. Privacy regulations and information regarding ICES data holdings can be found at [www.ICES.on.ca](http://www.ICES.on.ca) This data is often used for research purposes and has been validated. Further information is available from the Corresponding Author upon request.

Introduction {#sec005}
============

Varenicline is a partial nicotine receptor agonist used for smoking cessation.\[[@pone.0163681.ref001]--[@pone.0163681.ref004]\] Although it is generally well-tolerated, serious psychiatric adverse events including fatal and non-fatal self-harm have been noted in case-reports and post-marketing reporting.\[[@pone.0163681.ref005], [@pone.0163681.ref006]\] Concerns over these events have prompted the U.S. Food and Drug Administration (FDA) and other regulatory agencies to add warnings about self-harm and suicide to the product labelling and prescribing information of varenicline. However, the association between varenicline use and serious psychiatric adverse events remains unclear.\[[@pone.0163681.ref007]\] Clinical trials are not powered to detect rare adverse events such as suicide and often exclude patients with psychiatric comorbidies.\[[@pone.0163681.ref001]--[@pone.0163681.ref004], [@pone.0163681.ref008]\] and observational studies have been limited by small numbers of events. Moreover, there have been few studies comparing the risk of suicide between varenicline and bupropion, an antidepressant commonly prescribed for smoking cessation. We sought to examine the association between suicide or non-fatal self-harm and varenicline relative to bupropion using administrative claims databases.

Methods {#sec006}
=======

We conducted a population-based nested case-control study of Ontario adults (18 years and older) who were dispensed bupropion or varenicline between April 1, 2011 through March 31, 2015. We used Ontario's administrative databases to ascertain drug exposures and clinical outcomes. Specifically, we ascertained drug exposure using the Ontario Drug Benefit (ODB) database, drug coverage in Ontario is available for all residents with financial needs (due to high drug costs and/or low income) and all residents 65 years of age and older. We identified hospitalizations and emergency department visits using the Canadian Institute for Health Information\'s Discharge Abstract Database and National Ambulatory Care Reporting System, respectively. These datasets were linked using unique, encoded identifiers, were analyzed at the Institute for Clinical Evaluative Sciences (ICES), and are routinely used to examine drug safety.\[[@pone.0163681.ref009]--[@pone.0163681.ref012]\]

From within the cohort of patients receiving either varenicline or bupropion, we defined cases as patients with any emergency department (ED) visit or inpatient hospitalization associated with self-harm or suicide (International Classifications of Diseases, 10th edition X60-X84, Y10-Y19, and Y28) who were dispensed one of buproprion or varenicline in the 90 days prior. We restricted our analysis to prescriptions for Zyban® because this is the only formulation of bupropion covered solely as smoking cessation therapy by the Ontario Drug Benefit program. From within the same cohort, we selected up to 50 controls for each case and randomly assigned them an index date over the study period. Controls were eligible if they had no hospitalization or emergency department visits for self-harm/suicide at index, and had been prescribed one (but not both) of the study drugs in the prior 90 days. Controls and cases were matched on age (within 1 year), sex, history of hospitalization or ED visit for self-harm in the previous 5 years, use of any psychotropic medications in the previous 6 months, history of alcohol abuse in the previous 3 years, and admission to a mental health unit in the previous year. The study was approved by the research ethics board of Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

We summarized patient characteristics using descriptive statistics and compared cases and controls using standardized differences. We used conditional logistic regression to compare the risk of suicide/self-harm between varenicline and bupropion. We adjusted all models for potential confounders including socioeconomic status, Charlson comorbidity score, health care utilization (number of physicians visits and ED visits in the past year), number of psychiatrist visits (in the past year), past psychotropic use in previous 6 months (antidepressants, antipsychotics, benzodiazepines, mood stabilizers, and stimulants), psychiatric comorbidities, and total number of drugs dispensed in the past 180 days. Analyses were performed using SAS (version 9.2; SAS Institute Inc.).

Results {#sec007}
=======

We identified 331 cases and 5,346 matched-controls who were treated with varenicline or bupropion 90 days prior to their index date (**[Table 1](#pone.0163681.t001){ref-type="table"})**. Overall, cases were similar to controls with respect to important demographics and characteristics such as neighbourhood income status, urban status, age, and sex. As expected, cases were more likely to have visited the emergency department, seen a psychiatrist, spent more days in hospital, and had a greater burden of psychiatric morbidity. In our main analysis, we found no increase in risk of suicide/self-harm among varenicline users relative to bupropion users (adjusted odds ratio 1.15; 95% confidence interval 0.71 to 1.87) (**[Table 2](#pone.0163681.t002){ref-type="table"})**.

10.1371/journal.pone.0163681.t001

###### Baseline Characteristics for Cases and Matched Controls.

![](pone.0163681.t001){#pone.0163681.t001g}

  Characteristics                                                                    Cases              Controls           Standardized Difference
  ---------------------------------------------------------------------------------- ------------------ ------------------ -------------------------
  **Demographic Characteristics:**                                                   ** **              ** **              ** **
  Age at index date---Mean (SD)                                                      45.5 (12.1)        45.4 (12.1)        0.01
  Male---N (%)                                                                       154 (46.5%)        2,541 (46.5%)      0
  Income quintile- N (%)                                                                                                    
          1                                                                          140 (42.3%)        2,274 (44.6%)      0.06
          2                                                                          84 (25.4%)         1,266 (22.4%)      0.09
          3                                                                          48 (14.5%)         762 (14.9%)        0.02
          4                                                                          36 (10.9%)         624 (11.5%)        0.03
          5                                                                          22 (6.6%)          397 (6.1%)         0.03
  Urban residence---N (%)                                                            299 (90.3%)        4,501 (85.7%)      0.19
  **Measures of Comorbidity:**                                                       ** **              ** **              ** **
  Charlson Comorbidity Score:---N (%)                                                                                       
          No hospitalization                                                         171 (51.7%)        3,865 (64.3%)      0.31
          0                                                                          91 (27.5%)         705 (18.5%)        0.25
          1                                                                          37 (11.2%)         381 (10.1%)        0.04
          2+                                                                         32 (9.7%)          395 (7.0%)         0.11
  **Health Care Utilization:**                                                                                              
  Number of visits to ED in the past year---Median (IQR)                             2.0 (1.0--6.0)     1.4 (1.0--2.4)     0.44
  ED visit or Hospitalization for self-harm in the past 5 years---N (%)              94 (28.4%)         211 (28.4%)        0
  Number of visits to a family physician in the past year---Median (IQR)             12.0 (6.0--25.0)   13.1 (9.5--19.5)   0.22
  Number of Psychiatrist visits in the past year- N (%)                              146 (44.1%)        905 (31.6%)        0.30
  Days in hospital in past 1 year [\*](#t001fn001){ref-type="table-fn"}- Mean (SD)   10.0 (16.4)        1.9 (2.8)          0.87
  Admission to mental health unit in the past year---N (%)                           35 (10.6%)         48 (10.6%)         0
  **Psychiatric Disorders (measured in 3 years prior to index date):---**N (%)                                              
          Alcohol Abuse                                                              100 (30.2%)        374 (30.2%)        0
          Affective Disorder                                                         113 (34.1%)        629 (23.7%)        0.26
          Anxiety or sleep disorder                                                  286 (86.4%)        3,124 (71.2%)      0.50
          Psychosis, agitation, and related disorders                                98 (29.6%)         496 (19.6%)        0.26
          Other mental health disorders                                              279 (84.3%)        3,353 (74.4%)      0.32
  Number of distinct drugs used in past 6 months---Median (IQR)                      11.0 (7.0--16.0)   10.2 (7.4--12.3)   0.34
  Number of distinct psychotropic medications used in past 6 months---Median (IQR)   3.0 (2.0--5.0)     2.3 (1.9--3.0)     0.50
  **Past Medication Use (past 6 months):-** N (%)                                                                           
          Antidepressants (SSRIs)                                                    257 (77.6%)        3,537 (73.2%)      0.12
          Antidepressants (other)                                                    165 (49.8%)        1,256 (36.8%)      0.31
          Benzodiazepines                                                            196 (59.2%)        1,906 (42.8%)      0.40
          Mood Stabilizers                                                           104 (31.4%)        962 (20.5%)        0.29
          Stimulants                                                                 21 (6.3%)          160 (5.0%)         0.07

\*Note: Days in hospital in past 1 year is calculated only among those had at least 1 day in hospital

10.1371/journal.pone.0163681.t002

###### Association of varenicline compared to bupropion and self-harm.

![](pone.0163681.t002){#pone.0163681.t002g}

                          No. exposed cases (N)   No. Exposed controls(N)   Unadjusted OddsRatio (95% CI)   AdjustedOddsRatio (95% CI)
  ----------------------- ----------------------- ------------------------- ------------------------------- ----------------------------
  Varenicline             307                     4,764                     1.35 (0.86 to 2.11)             1.15 (0.71 to 1.87)
  Bupropion (reference)   24                      582                       1.00                            1.00

Interpretation {#sec008}
==============

In this observational study, we did not find a significantly higher risk of suicide/self-harm with varenicline relative to bupropion use for smoking cessation. To our knowledge, this is the largest study examining this question.

Our findings align with four previously published observational studies and recent FDA reports.\[[@pone.0163681.ref013]--[@pone.0163681.ref016]\] All observational studies found no increased risk with varenicline use, but confidence in the findings was limited due to smaller sample sizes. Two cohort studies using the UK General Practice Research Data (GPRD) database found similar incidences of fatal and nonfatal self-harm among patients prescribed varenicline or nicotine replacement therapy (0.08% and 0.09%, respectively). A similar incidence was found among bupropion users (0.06%), although a direct comparison with varenicline-treated patients was not made. A 2015 update using the same UK data found similar results with varenicline not being associated with an increased risk of self-harm (adjusted hazard ratio 0.56; (95% confidence interval 0.46 to 0.68).\[[@pone.0163681.ref008]\] The protective estimate with varenicline may have been due to large differences in baseline characteristics which may have lead to selection bias. A Danish study comparing 17,935 users of varenicline with the same number of bupropion-treated patients found no difference in the incidence of psychiatric adverse events (0.22% vs. 0.26%, respectively), although suicide was not examined as an outcome.\[[@pone.0163681.ref014]\] Additionally, a meta-analysis of 18 trials submitted to the FDA by the manufacturer of varenicline found no statistically significant excess risk of self-harm compared to placebo. The same meta-analysis found no risk of suicidal ideation, hostility, and psychiatric disorders.\[[@pone.0163681.ref017]\] Ongoing manufacturer-sponsored clinical trials designed to address this question are scheduled to be published in the upcoming year.\[[@pone.0163681.ref018]\]

Our study has some limitations that warrant emphasis. First, restricting our analysis to Zyban® may have decreased the number of actual cases associated with off-label use of other bupropion formulations. However, this is unlikely because Zyban® was wholly reimbursed for this indication during our study period. Second, we are unable to identify use of other smoking cessation agents (e.g. nicotine replacement therapy), or the use of non-pharmacological-based smoking cessation programs. Third, we are unable to identify suicides that did not present to the emergency department or hospital and thus may have an underrepresentation of the number of cases in both groups. Lastly, due to the impact of concerns with varenicline and neuropsychiatric side effects, there may be increased aversion to prescribing varenicline to those at higher risk of self-harm. However, we believe that this aversion can be extended to both medications and thus would not impact our findings.

In conclusion, varenicline was not associated with a higher risk of suicide/self-harm relative to bupropion. Although our findings are not meant to endorse preferential use of varenicline, our study reinforces the prevailing view that varenicline does not impart an excess risk of suicide relative to other smoking cessation therapies. Future clinical trials are important to clarify the comparative safety of varenicline but we urge the importance of observational work such as our study to give a balanced view of real-world safety.
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